Sentences with phrase «tumor burden»

"Tumor burden" refers to the amount or extent of cancer cells present in a person's body. It indicates how much cancer has spread or multiplied in the body, showing the overall impact and size of the tumor or tumors. Full definition
However, while imaging has improved, some of the patients have more tumor burden in the liver transplant than seen on imaging.
Benefits include reduction of tumor burden, delayed cancer progression, and overall improvement in survival in some cases.
Average tumor burden and standard deviations were derived from at least four animals per group.
Accordingly, rapamycin has been found to extend lifespan and reduce tumor burden in mouse lines with a range of early - onset cancers (40, 41).
[18] Clearly, the higher tumor burden at baseline in stage IV patients adversely affected responses.
Rashid OM, Nagahashi M, Ramachandran S, Yamada A, Graham L, Milstien S, Spiegel S, Bear HD, Takabe K. Resection of the Primary Tumor Improves Survival in Metastatic Breast Cancer by Reduction of Overall Tumor Burden.
«In this study we've shown five distinct ways — by quantifying tumor burden, identifying disease subtype, cataloging mutations, predicting transformation and providing early warnings of recurrence — that circulating tumor DNA can yield potentially clinically useful information,» said Diehn.
Pooled data show PET imaging of metabolic tumor burden at diagnosis helps identify patients most at risk of FL recurrence.
(b) Quantitative analysis of the metastatic tumor burden in the lung.
Interest in liquid biopsy has escalated in recent years due to the minimally invasive sampling method, potential to overcome the challenges of tumor heterogeneity, and the potential for longitudinal monitoring of tumor burden through serial sampling.
Most significantly, intravenous treatment of tumor - bearing mice with synthetic miR - 34a reduced tumor burden by half in one tumor type.
Positron emission tomography (PET) imaging of metabolic tumor burden at diagnosis and after induction therapy can help identify patients most at risk of follicular lymphoma (FL) recurrence, but more work is needed to differentiate high - risk and moderate - risk patients, suggested findings from a pooled analysis of data from three prospective clinical trials, published in Blood.
«The traditional staging system does not account for the total volume of disease or baseline tumor burden,» Dr. Joseph says.
The investigators utilized a targeting method called RNA interference (RNAi) which, when delivered via these natural nanoparticles or exosomes, zero in on mutant KRAS in pancreas cancer cells, impacting tumor burden and survival in multiple pancreas cancer models.
In a study presented in the featured clinical investigation article of the November issue of The Journal of Nuclear Medicine, they used 18F - fluorodeoxyglucose (FDG) PET / CT imaging to show that the amount of cell - free tumor DNA circulating in the bloodstream correlates with tumor metabolism (linked to cancer aggressiveness), not tumor burden (amount of cancer in the body).
The approach was most successful in making a difference in samples from the two patients in which the smaller - sized tumor DNA was not readily apparent, which may represent patients with low tumor burden and previously difficult to detect circulating tumor DNA.
The study, «Salmonella Bacterial Monotherapy Reduces Autochthonous Prostate Tumor Burden in the TRAMP Mouse Model,» was recently published in PLOS ONE.
Similarly, histological analyses revealed a decrease in bone tumor burden in mice treated with the allosteric inhibitor of the ABL kinases (Fig. 3, E and F).
Conditional expression of fascin led to decrease in mice survival and increase in tumor burden compared to control animals.
Changes in tumor burden over the course of treatment were typical of the response kinetics seen with T - VEC, she noted.
Six days later, the mice were injected with luciferin, imaged with IVIS 50 optical imaging (Xenogen), and randomized into the study groups (6 mice per group) based on bioluminescent tumor burden.
In addition to monitoring overall survival, we assessed tumor burden, as measured by bioluminescence imaging, during the first 22 days of treatment (Figure 3).
The opportunity to detect a statistically significant difference was limited though, due to the higher rate of early death in the control group, and increased overall survival in (+)- JQ1 treated mice before the pre-specified tumor burden analysis endpoint.
4) The planned comparison of tumor burden from mice treated with (+)- JQ1 compared to vehicle control was not statistically significant, nor was the planned comparison between (+)- JQ1 treatment and -LRB--)- JQ1.
The immune checkpoint blockade drug nivolumab reduced tumor burden in 24.4 percent of patients with metastatic bladder cancer, regardless of whether their tumors had a biomarker related to the drug's target, according to clinical trial results from The University of Texas MD Anderson Cancer Center.
Indeed, the authors point out that Ipilimumab might better effect recurrence - free survival than adjuvant interferon and should be considered as an option by oncologists in this field considering its activity across subgroups including those with high tumor burden.
Understanding a patient's overall tumor burden through genomic testing, says Carbone, could help identify patients most likely to benefit from immunotherapy before therapy ever begins.
Metastatic tumor burden of each animal was calculated by combining tumor volumes from four lobes of lungs.
In one report, a patient with an L576P KIT mutation in whom imatinib therapy had previously failed experienced marked reduction in tumor burden in response to dasatinib treatment.
Consequently, TruePrime LB provides a method for assessing cancer genome information from all patients, regardless of tumor burden, with superior sensitivity and specificity.
They cross the blood - brain / blood - tumor barrier, and accumulate within brain tumor sites, where they target oncogenes, regulate cell growth and differentiation, reduce tumor burden and prolong survival in our mouse models.»
These results suggest that cfDNA might better reflect tumors» biological behavior and aggressiveness than tumor burden in metastatic NSCLC.
In mice with liver metastases, expression of LIGHT similarly provoked a potent immune response that resulted in a significant decrease in tumor burden.
The treatment resulted in a reduced tumor burden and extended the lifespans of the mice by more than 30 percent.
In animal models, the modified T cells greatly reduced the tumor burden and prolonged overall survival: All mice that received the modified T cells were alive 44 days after treatment versus 29 percent and 17 percent of the study's two control groups.
«Given the high discrepancy of genetic findings between a primary tumor and metastatic sites within the same patient, our study suggests we should concentrate on metastatic sites that represent the majority of the tumor burden.
More than a year after initiating treatment, the patient has a 77 percent reduction in tumor burden and no new metastases.
Circulating cell - free DNA (cfDNA) isolated from plasma or serum by noninvasive procedures can serve as a «liquid biopsy» and has potential as a biomarker for the tumor burden and survival prediction of breast cancer (BC).
However, he noted that there was a tendency to treat patients with higher tumor burdens (> 5 % blasts), and outcomes in this setting are less than optimal.
After three weeks of treatment, Shaw and his team saw a modest reduction in tumor burden in the mice.
Among the possible reasons for this difference, Venook suggested that the tumor burden of patients with tumors on the right side may be greater than the tumor burden of patients with cancer on the left side.
To quantify the tumor burden, each image was first annotated with the National Institutes of Health ImageJ software to identify measurable nodules on the surface of the lung.
«Based on these data we feel there is no evidence in difference in tumor burden to explain the sidedness differential,» Venook said.
An analysis of combined results from these earlier studies found that metformin use was associated with a significant decrease in cancer risk, tumor burden and cancer mortality.
The researchers therefore looked at possible indicators of tumor burden, including direct measurements such as lactate dehydrogenase and the number or volume of metastases, or indirect evidence such as leaving the primary tumor in place or if the goal of treatment was palliation.
Excitingly, a single dose of any of the three NK cell populations assessed led to a significant reduction in tumor burden, although the iPSC ‐ derived NK group demonstrating a trend toward overall better activity.
Finally, knocking down CD44 with a short hairpin RNA produced the same results as treating cells with miR - 34a did — reduced tumor development, tumor burden and metastases.
a b c d e f g h i j k l m n o p q r s t u v w x y z